A Randomised Phase II Open-label Study With a Phase Ib Safety lead-in Cohort of ONCOS-102, an Immune-priming GM-CSF Coding Oncolytic Adenovirus, and Pemetrexed/Cisplatin in Patients With Unresectable Malignant Pleural Mesothelioma

NCT02879669 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

31

Enrollment

INDUSTRY

Sponsor class

Conditions

To Determine Safety, Tolerability and Efficacy of ONCOS-102 in Combination With Chemotherapy

Interventions

BIOLOGICAL: ONCOS-102
DRUG: Pemetrexed/cisplatin (carboplatin)
DRUG: Cyclophosphamide

Sponsor

Targovax Oy

Collaborators

[object Object]